ORMP

Oramed Pharmaceuticals Inc. NASDAQ Listed May 1, 2007

Healthcare ·Biotechnology ·US · oramed.com

$3.91

Mkt Cap $158.1M

52w Low $1.98 86.2% of range 52w High $4.22

50d MA $3.61 200d MA $2.89

P/E (TTM) 2.6x

EV/EBITDA -4.8x

P/B 1.9x

Debt/Equity 0.0x

ROE 32.1%

P/FCF -12.9x

RSI (14) —

ATR (14) —

Beta 1.25

50d MA $3.61

200d MA $2.89

Avg Volume 134.5K

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

SIC Code

2834

CIK (SEC)

1176309

Phone

844 967 2633

1185 Avenue of the Americas · New York City, NY 10036 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-0.08	-0.06	+25.0%	3.32	-0.9%	-0.3%	-1.2%	+2.4%	+2.1%	+3.0%	—
Nov 13, 2025	AMC	-0.04	1.13	+2925.0%	2.40	-2.1%	-2.9%	-2.5%	+3.8%	+4.2%	+0.8%	—
Aug 14, 2025	AMC	-0.04	-0.05	-25.0%	2.12	-5.7%	-1.9%	-1.9%	-2.8%	-2.4%	-2.8%	—
May 15, 2025	AMC	-0.03	-0.19	-533.3%	2.20	+0.0%	-2.3%	-2.7%	-2.3%	-4.1%	-2.3%	—
Mar 27, 2025	AMC	-0.03	0.01	+133.3%	2.30	+0.9%	-3.9%	-7.0%	-7.4%	-4.3%	-6.1%	—
Nov 7, 2024	AMC	-0.00	-0.48	-9695.9%	2.38	-0.8%	-2.9%	-2.5%	-1.7%	-2.5%	-1.7%	—
Aug 14, 2024	AMC	0.01	0.26	+2500.0%	2.24	+7.1%	+4.9%	+4.5%	+5.8%	+7.1%	+10.3%	—
May 9, 2024	AMC	0.02	0.04	+100.0%	2.38	-0.4%	+0.8%	+1.3%	+3.8%	+0.4%	-2.1%	—
Mar 6, 2024	AMC	-0.12	-0.08	+33.3%	2.87	-2.4%	-0.3%	+3.8%	+2.4%	-0.3%	-3.5%	—
Nov 9, 2023	AMC	-0.09	-0.08	+11.1%	1.95	+1.0%	-1.5%	+2.1%	+5.1%	+5.6%	+4.6%	—
Aug 10, 2023	AMC	-0.11	-0.03	+72.7%	3.19	-0.6%	+2.5%	-2.2%	-1.9%	-8.8%	-1.3%	—
May 11, 2023	AMC	-0.23	-0.08	+65.2%	2.82	-0.4%	+0.4%	+11.0%	+37.9%	+28.7%	+45.7%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 17	Canaccord Genuity	Maintains	Hold → Hold	—	$3.89	$3.89	+0.0%	-6.7%	+5.7%	+14.7%	+13.9%	+14.9%
Jan 17	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$2.25	$2.16	-4.0%	-10.2%	-3.1%	-6.2%	-8.4%	-9.3%
Jan 12	Canaccord Genuity	Downgrade	Buy → Hold	—	$10.79	$2.37	-78.0%	-76.5%	-79.1%	-81.3%	-79.8%	-80.4%
May 16	Aegis Capital	Maintains	Buy → Buy	—	$4.57	$4.62	+1.1%	+7.0%	+12.5%	-2.6%	-1.1%	-0.9%
Feb 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.63	$10.86	+2.2%	-0.7%	-4.5%	-10.3%	-4.6%	-4.7%
Nov 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.31	$18.52	+1.1%	+5.0%	-3.4%	-4.3%	-15.7%	-14.9%
Nov 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.21	$21.19	+4.8%	-9.4%	-4.9%	-12.5%	-13.3%	-23.7%
Nov 2	Aegis Capital	Maintains	Buy → Buy	—	$25.08	$25.47	+1.6%	+14.8%	+0.0%	+5.6%	+7.0%	+18.6%
Jul 29	Canaccord Genuity	Maintains	Buy → Buy	—	$13.81	$13.94	+0.9%	+5.6%	+2.8%	+8.2%	+12.2%	+9.3%
Jun 8	Aegis Capital	Maintains	Buy → Buy	—	$13.60	$13.65	+0.4%	+1.8%	+7.3%	+6.4%	+4.2%	+4.8%
Apr 20	Canaccord Genuity	Maintains	Buy → Buy	—	$8.46	$8.82	+4.3%	-1.4%	+9.0%	+10.5%	+15.6%	+21.2%
Feb 9	National Securities Corporation	Maintains	Buy → Buy	—	$10.43	$10.65	+2.1%	+0.1%	-3.6%	-2.2%	+5.5%	+6.5%
Jan 27	Aegis Capital	Maintains	Buy → Buy	—	$6.84	$6.46	-5.6%	+1.5%	+2.3%	+6.1%	+26.2%	+37.9%
Jul 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.33	$3.42	+2.7%	+3.3%	+7.8%	+21.9%	+22.5%	+19.5%
Jun 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.05	$4.12	+1.7%	+1.7%	-3.5%	-8.1%	-9.6%	-10.9%
Sep 11	Ladenburg Thalmann	Maintains	Buy → Buy	—	$2.97	$3.09	+4.0%	-2.0%	+1.0%	+2.7%	+1.7%	+6.1%
Nov 19	FBR Capital	Maintains	Outperform → Outperform	—	$7.09	$7.23	+2.0%	+3.8%	+16.8%	+13.0%	+7.9%	+7.6%
Oct 1	H.C. Wainwright	Maintains	Buy → Buy	—	$5.47	$5.72	+4.6%	+6.4%	+13.5%	+18.5%	+13.0%	+16.5%
Dec 4	Aegis Capital	Maintains	Buy → Buy	—	$8.03	$8.03	+0.0%	+0.7%	-1.6%	-2.7%	-1.9%	-1.2%

Data updated apr 26, 2026 5:56pm · Source: massive.com